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Background: Acute myeloid leukemia (AML) is a hematopoietic malignancy with a dismal outcome in the
majority of cases. A detailed understanding of the genetic alterations and gene expression changes that
contribute to its pathogenesis is important to improve prognostication, disease monitoring, and therapy. In this
context, leukemia-associated misexpression of microRNAs (miRNAs) has been studied, but no coherent picture has
emerged yet, thus warranting further investigations.
Methods: The expression of 636 human miRNAs was compared between samples from 52 patients with AML and 13
healthy individuals by highly specific locked nucleic acid (LNA) based microarray technology. The levels of individual
mature miRNAs and of primary miRNAs (pri-miRs) were determined by quantitative reverse transcriptase (qRT) PCR.
Transfections and infections of human cell lines were performed using standard procedures.
Results: 64 miRNAs were significantly differentially expressed between AML and controls. Further studies on the
clustered miRNAs 221 and 222, already known to act as oncogenes in other tumor types, revealed a deficiency of
human myeloid cell lines to process vector derived precursor transcripts. Moreover, endogenous pri-miR-221/222 was
overexpressed to a substantially higher extent than its mature products in most primary AML samples, indicating
that its transcription was enhanced, but processing was rate limiting, in these cells. Comparison of samples from
the times of diagnosis, remission, and relapse of AML demonstrated that pri-miR-221/222 levels faithfully reflected
the stage of disease.
Conclusions: Expression of some miRNAs is strongly regulated at the posttranscriptional level in AML.
Pri-miR-221/222 represents a novel molecular marker and putative oncogene in this disease.
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Acute myeloid leukemia (AML) is a frequently fatal malig-
nant disease of hematopoietic stem and progenitor cells
(HSPCs). Prognostic factors include patient age, antecedent
hematological disease, preceding cytotoxic treatments for a
primary disorder, and the presence of specific cytogenetic,
molecular, and epigenetic aberrations [1-7]. Identification
and investigation of such somatic genetic alterations has
enhanced our understanding of disease biology, augments* Correspondence: rotraud.wieser@meduniwien.ac.at
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reproduction in any medium, provided the ordiagnosis and prognostication, and may aid monitoring of
the course of disease [1,3,7,8]. Although cytogenetics and
molecular genetics have already facilitated great progress
in these respects, novel technologies like next generation
sequencing and biological breakthroughs like the iden-
tification of microRNAs (miRNAs) and long noncoding
RNAs (lncRNAs) as entirely novel gene classes still
provide fundamental additional insights. In this context,
the expression, functions, and potential prognostic value
of miRNAs in AML have been studied by a number of
research groups over the past few years [9-15]. In contrast,
little is known about the expression and roles of lncRNAs
in this disease.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which typically regulate multiple target genes at the levels
of mRNA stability and translation efficiency [16,17]. They
are excised through sequential processing steps from
larger, usually polymerase II transcribed, RNA molecules
termed primary miRNAs (pri-miRNAs). One pri-miRNA
molecule may give rise to one or several miRNA species,
with the respective genomic region referred to as a miRNA
cluster in the latter case [18]. Classical pri-miRNA pro-
cessing consists of two endonucleolytic cleavage steps: the
first one is carried out in the nucleus by the RNase Drosha
and gives rise to ~70 nt long, hairpin shaped precursor
(pre-) miRNA molecules. These are exported to the cyto-
plasm and further processed by another RNase, Dicer, to
yield mature miRNAs [18-21]. After incorporation into
the RNA induced silencing complex (RISC), miRNAs
recognize their target mRNAs through a 7–8 nt seed
sequence and repress their translation and stability
[16,17,20,21]. In addition to this well described way of
action of mature miRNAs, biochemical and biological
functions have recently been ascribed to some pri-miRNAs
[22,23], thus greatly expanding the potential biological
relevance of miRNA genes.
Large scale expression analyses of mature miRNAs
revealed specific miRNA patterns that were associated
with recurrent genetic abnormalities in AML [10-12,24].
Certain miRNAs were deregulated in AML compared to
healthy bone marrow (BM), peripheral blood (PB), or
CD34 positive (CD34+) HSPCs [10-12,24,25], and miRNA
signatures predictive of survival have been identified
[9,10]. However, results from different research groups
exhibited only limited concordance, most likely due to
differences between patient collectives, types of healthy
control, and methodologies [13].
In this study, we re-addressed the question which
miRNAs are differentially expressed between AML and
healthy controls, and therefore might contribute to
leukemogenesis. Using highly specific locked nucleic
acid (LNA) oligonucleotide arrays capable of detecting
559 annotated and 77 proprietary human miRNAs, 64
miRNAs were found to be significantly misexpressed
in AML. Further studies on the clustered miRNAs 221
and 222 revealed that pri-miR221/222 was overexpressed
to a much higher extent than its mature products, which
is best explained by an increased rate of transcription on
the background of a limited processing capacity. Because
pri-miR-221/222 is strongly overexpressed in a large pro-
portion of patients with AML, it may represent a novel
molecular marker and a putative oncogene in this disease.
Methods
Primary samples from patients and controls
This study was approved by the Ethics Committee of the
Medical University of Vienna (EK no 609/2011). In somecases, archival samples were used. Written informed
consent was obtained prior to sample collection from
all other subjects. Data were analyzed anonymously.
For miRNA microarray hybridization, 52 AML PB
samples and 13 control samples were used (Additional
file 1: Tables S1A and B). The AML samples had been
collected at the time of diagnosis, strongly enriched for
leukemic blasts using Ficoll, and vitally frozen. Of the
healthy control samples, three were CD34+ HPSCs
enriched from bone marrow (BM) and five were BM
mononuclear cells (MNCs) (all purchased from Lonza,
Basel, Switzerland). Another five were PB samples from
healthy volunteers, and were subjected to erythrocyte lysis
prior to RNA isolation (Additional file 1: Table S1A).
Twenty-two and 9 of these AML and control samples,
respectively, were also used for qRT-PCR for mature
miR-221 and 222. Characteristics of 27 additional diag-
nostic AML samples used to determine the ratio between
pri-miR-221/222 and mature miR-221, as well as the
expression of pri-miR-221/222 and other pri-miRNAs
are summarized in Additional file 1: Table S1C. Eight
additional control samples used for qRT-PCR experiments
are included in Additional file 1: Table S1A. To investigate
pri-miR-221/222 expression during the course of disease,
four paired samples from the time of diagnosis and remis-
sion and three paired samples from the time of diagnosis
and relapse were analyzed (Additional file 1: Table S1D).
Production and hybridization of miRNA microarrays, and
primary data analysis
miRNA microarrays were produced as previously described
[26,27]. Briefly, LNA modified oligonucleotide probes
specific for the 559 human miRNAs contained in miRBase
version 9.2 (http://www.mirbase.org/) as well as probes
for 77 proprietary miRPlus sequences (Exiqon, Vedbaek,
Denmark) were spotted onto Hisens epoxy-coated glass
slides (Schott Nexterion, Louisville, KY, USA) in eight
replicates.
RNA was extracted with Trizol (Life Technologies,
Carlsbad, CA, USA), subjected to quality control using a
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA), and labelled with Hy3 using the miRCURY™ LNA
microRNA array labelling kit (Exiqon). A Hy5 labelled
mix of all samples was included in each hybridization as a
common reference. Arrays were hybridized overnight at
60°C in microarray hybridization chambers (Corning,
Corning, NY, USA). Hybridization and wash buffers from
the miRCURY LNA microRNA Array Kit (Exiqon) were
used according to the manufacturer’s instructions. Arrays
were scanned with a GenePix 4100A Microarray Scanner
and evaluated with GenpixPro 5.1 software (Molecular
Devices, Sunnyvale, CA, USA). Primary data analysis was
performed using ArrayNorm [28]. Features were filtered
for low quality spots, the local background was subtracted,
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between the sample of interest and the common reference
were log2 transformed.
Cell lines, miRNA expression vectors, stable transfections,
and infections
KG1 and KG1a cells [29] were obtained from the
German Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany. HNT34 [30] and MPD [31]
cells were kindly provided by Dr. Hiroyuki Hamaguchi,
Musashino Red Cross Hospital, Tokyo, Japan, and Dr.
Cassandra Paul, Wright State University, Dayton. Ohio,
USA, respectively. HL60 [32], HEL [33], U937 [34],
HeLa [35], MCF7 [36], and 293 T [37] cells were obtained
from cell culture collections of the Medical University of
Vienna. All cell lines were regularly tested for mycoplasma
contamination.
The human myeloid cell lines KG1, HL60, HEL, U937,
MPD, and HNT34 were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium supplemented with 10%
Fetal Bovine Serum (FBS) and 1%Penicillin-Strepto-
mycin-Glutamine (PSG; all from Life Technologies,
Carlsbad, CA, USA) in a humidified incubator at 37°C
and 5%CO2. The same media were used for KG1a cells,
except that they contained 20%FBS. The adherent cell lines
HeLa, MCF7, and 293 T were maintained in Dulbecco’s
Modified Eagle Medium (DMEM; Life Technologies) with
10%FBS and 1%PSG.
Plasmid miR-Vec-221/222, which contains the miR-
221/222 cluster along with a blasticidin resistence gene
in the pMSCV backbone, as well as the corresponding
empty vector (miR-Vec) were kindly provided by the
Agami lab [38]. They were stably transfected into
HL60 cells by electroporation and transfectants were
selected using 2 μg/ml Blasticidin (Invivogen, San
Diego, CA, USA).
pEZX-MR03-miR-221 (Homo sapiens microRNA miR-
221 stem-loop expression clone, #HMIR0369), an HIV
based lentiviral vector containing the miR-221 precursor,
and pEZX-MR01-control (#CMIR0001-MR01), which con-
tains a scrambled sequence instead, were obtained from
GeneCopoeia (Rockville, Maryland, USA). They were
infected into the myeloid cell lines HL60, KG-1, and
KG-1a using standard procedures [39]. Infected cells
were sorted for GFP positivity on a FACS Aria (BD
Biosciences, NJ, USA).
RNA extraction, cDNA synthesis, and quantitative reverse
transcriptase PCR (qRT-PCR)
Total RNA was isolated from primary samples and cell
lines using Trizol (Life Technologies). For detection of
pri-miRNAs, RNA was treated with DNase I and converted
to cDNA with M-MLV reverse transcriptase primed by
random hexamer oligonucleotides (all reagents from LifeTechnologies). qRT-PCR was performed in an ABI Step
One Plus sequence detection system (Applied Biosystems,
Life Technologies) using the Mesa Green qPCR Master
Mix Plus (Eurogentec, Liège, Belgium) and the primers
listed in Additional file 2: Table S2A (synthesized by
MWG Eurofins, Ebersberg, Germany). All primer pairs
were subjected to standard curve analysis and yielded
slopes between −3.0 and −3.5, indicating optimal or near
optimal amplification efficiencies. Levels of mature miR-
221 and miR-222 and of RNU6B were measured using
Taqman assays (ID000524, hsa-miR-221 TaqMan Assay;
ID002276, hsa-miR-222 TaqMan Assay; ID001093, mature
miR control-RNU6B TaqMan Assay; Applied Biosystems).
qRT-PCR reactions were performed in triplicate. The
relative expression of pri-miRNAs compared to the
housekeeping gene beta-2-microglobulin, and of mature
miRNAs relative to RNU6B, were calculated according to
the ΔΔCt method [40].
RNA deep sequencing analysis and prediction of putative
pri-miR 221/222 transcripts
RNA deep sequencing optimized for detection of
lncRNAs was performed as described [41]. In short, total
RNA was extracted from human Hs27 foreskin fibroblasts
with TRIreagent (Sigma-Aldrich, Seelze, Germany), treated
with DNaseI (DNA-free kit, Ambion, Life Technologies),
depleted of ribosomal RNA using RiboMinus Transcrip-
tome Isolation Kit Human/Mouse (Life Technologies)
and Ribo-Zero rRNA Removal Kit Human/Mouse/Rat
(Epicentre Biotechnologies, Madison, WI, USA), and
fragmented by hydrolysis. Double stranded cDNA was
generated with SuperScript II Reverse Transcriptase
(Life Technologies). The RNA-Seq library was prepared
using the Chip-Seq DNA Sample Prep Kit (Illumina, San
Diego, CA, USA), and sequenced using an Illumina
Genome Analyzer II and Illumina HiSeq 2000 systems.
36 bp and 51 bp single end reads were aligned to human
genome build hg18 using Bowtie (http://bowtie-bio.
sourceforge.net/index.shtml) and visualized on the Uni-
versity of California Santa Cruz (UCSC) genome browser
(http://genome.ucsc.edu/) (Vlatkovic IM, manuscript in
preparation), together with publically available global
run-on sequencing (GRO-Seq) data [42], ENCODE
histone modification Chip-Seq data generated by the
BROAD Institute, and RefSeq Genes.
Cloning of reporter vectors, transient transfections, and
luciferase reporter assays
Two fragments surrounding the transcription start site
predicted for the putative 28.2 kb pri-miR-221/222
transcript were amplified from PB leukocyte genomic
DNA using the primers shown in Additional file 2: Table
S2B and Phusion High Fidelity Polymerase (New England
Biolabs, Ipswich, MA, USA). The resulting PCR products
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(Promega, Madison, WI, USA) using the SacI and XhoI
restriction sites engineered onto the PCR primers to
generate reporter vectors pGL3-P(−1874/+45) and pGL3-
P(+17/+1952).
Subconfluent cultures of 293 T, HeLa and MCF7 cells
growing in 24-well plates were transfected with 1 μg of
the indicated pGL3-P vector derivative and 30 ng of the
renilla luciferase vector pGL 4.70 (Promega, Madison,
WI, USA), using JetPei Transfection Reagent (Polyplus
Transfections, Illkirch, France) according to the manufac-
turer’s instructions. 48 h later, luciferase activities were
measured using a Tristar LB941 (Berthold Technologies,
Bad Wildbad, Germany) and the Dual-Luciferase Reporter
Assay (Promega, Madison, WI, USA). Firefly luciferase
activity was normalized to Renilla luciferase activity to
control for transfection efficiency.Statistical analyses
For statistical analyses of miRNA microarray data, only
features with a valid human miRNA annotation, and
which were detectable in at least half of the relevant
samples (i.e., 27, 2, 3, and 3 of the AML, control CD34+,
control BM, and control PB samples, respectively) were
considered. One-way ANOVA was performed to test if a
miRNA was differentially expressed in one of the classes,
and a moderated t-test (R/Biconductor package limma)
was used to test if a miRNA was differentially expressed
between two respective classes. Resulting p-values were
adjusted for multiple hypothesis testing based on the
false discovery rate (FDR) [43].
Spearman’s rank correlation was used to determine
associations between miRNA expression as a continuous
variable and the clinical parameters age, white blood cell
count, percentage of blasts, lactate dehydrogenase (LDH),
and cytogenetic risk. The point biserial correlation coeffi-
cient was used to show associations between miRNA
expression and the dichotomous parameters gender and
achievement of complete remission (CR), and significance
was probed using the Wilcoxon rank-sum test. Associa-
tions between miRNA expression levels and the FAB type
were given by the eta coefficient and significance was
calculated by one-way ANOVA. All p-values were adjusted
for multiple hypothesis testing based on the FDR [43]. All
calculations were performed using R.
For experiments using cultured cells at least three
independent biological replicates were performed. Results
are expressed as means ± standard error of the mean
(SEM), or, where indicated, one representative experiment
with standard deviations (SDs) from technical replicates is
shown. Student’s two-tailed t-test at a significance level of
0.05 was employed to probe differences between groups
for statistical significance.Results
Microarray analyses identify miRNAs deregulated in AML
compared to healthy controls
To compare miRNA expression profiles between AML and
normal controls, RNA from 52 AML samples (Additional
file 1: Table S1B; enriched for leukemic blasts through
Ficoll purification) and 13 healthy donors (5 peripheral
blood (PB), 5 bone marrow (BM), and 3 BM CD34+;
Additional file 1: Table S1A) was hybridized to microarrays
containing LNA probes specifically detecting 559 human
miRNAs deposited in miRBase 9.2 as well as 77 proprietary
miRPlus sequences. Only miRNAs that were expressed in
more than half of each the AML, healthy PB, healthy
BM, and healthy CD34+ samples were considered for the
respective comparisons. At a false discovery rate (FDR)
of <5%, 3 miRNAs were up- and 10 downregulated in
AML versus control CD34+ cells. 23 miRNAs were up-
and 22 downregulated in AML compared to healthy BM,
and 17 miRNAs were expressed at higher and 19 at lower
levels in AML than in normal PB. 22 of these miRNAs
were deregulated compared to two out of the three
control tissues, and only four showed significantly
altered expression with respect to all three types of
control (Additional file 3: Table S3).
miRNA expression patterns were also tested for associa-
tions with preclinical and clinical parameters, namely, sex,
age, French-Amercian-British (FAB) type, white blood cell
count (WBC), blast percentage, lactate dehydrogenase
(LDH) levels, cytogenetic risk, and achievement of complete
remission (CR). At an FDR of <5%, significant associations
were found between miRNA levels and blast percentage,
cytogenetic risk, and sex (Additional file 4: Table S4).
Myeloid leukemia cell lines and primary AML samples
display a limited pri-miR-221/222 processing capacity
miR-221 and miR-222, which together form a cluster
located in chromosome band Xp11.3, were chosen for
further analyses because i) according to our array data they
were among the most strongly overexpressed miRNAs in
AML (Additional file 3: Table S3); ii) they are two of only
a few miRNAs consistently reported to be overexpressed
in AML [12,24,25,44]; and iii) they had been implicated as
oncogenes in a number of other malignancies [38,45-49].
qRT-PCR confirmed that mature miR-221 was signifi-
cantly upregulated in AML compared to healthy controls
(Figure 1A). For miR-222, a trend towards differential
expression was observed (Figure 1B).
To study the biological effects of miR-221 and miR-222
in human myeloid cells, we introduced suitable expression
vectors into the cell lines HL60, KG1, and KG1a. However,
neither blasticidin resistant HL60 clones obtained after
transfection with miR-Vec-221/222 [38], nor GFP positive
HL60, KG1, or KG1a cell populations sorted after infection
with pEZX-MR03-miR-221 exhibited increased expression
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Figure 1 Mature miR-221 is overexpressed in AML. 22 blast-
enriched AML samples and 9 healthy controls (3 CD34+, 3 BM, 3 PB),
all of which had also been included in the microarray experiments,
were subjected to Taqman qRT-PCR to measure mature miR-221
(A) or miR-222 (B). Expression values were calculated according to
the ΔΔCt method [40], with RNU6B as internal reference and PB
from healthy donor A as calibrator. *, p < 0.05; n.s., not significant
(miR-222, p = 0.064).
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Figure 2 Malignant human hematopoietic cells display
impaired pri-miR-221/222 processing capacity. Mature miR-221
was measured by qRT-PCR, normalized to RNU6B, and expressed
relative to ß-2-microglobulin-normalized pri-miR-221/222. A) Human
myeloid cell lines, and HeLa cells as a reference; B) primary AML
samples (n = 8; Additional file 1: Table S1B), enriched for blasts
through Ficoll gradient purification, and normal control PB (squares;
n = 4) and BM (triangles; n = 2) samples (Additional file 1: Table S1A).
HeLa cells were used as a calibrator in both experiments. *, p < 0.05;
***, p < 0.001.
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S1A, and data not shown). In contrast, miR-221 was clearly
elevated after transient transfection of HeLa cells with
pEZX-MR03-miR-221 (Additional file 5: Figure S1B),
demonstrating that this vector was functional. Furthermore,
qPCR showed that, other than the mature miR-221, its
precursor was indeed overexpressed in the pEZX-
MR03-miR-221 infected myeloid cell lines (Additional
file 5: Figure S1C), indicating that these cell lines are able
to transcribe pre-miR-221 from the pEZX-MR03 vector,
but process it inefficiently, possibly due to a saturation
effect.
To investigate whether the presumed processing defi-
ciency also affected endogenous miR-221/222, qRT-PCR
was performed on a panel of human myeloid cell lines.
Because PCR cannot selectively measure pre- versus
pri-miRNAs, and efficient reverse transcription of the short
pre-miRNA molecules into full-length, PCR amplifiable
cDNAs is unlikely based on technical considerations, the
RNA species expected to be predominantly measured in
these assays is pri-miR-221/222. The miR-221:pri-miR-
221/222 ratio was moderately decreased in the myeloid cell
lines compared to HeLa cells (Figure 2A), indicating that
the capacity of myeloid cells to process endogenous
pri-miR-221/222 may be compromised to some extent.More importantly, the miR-221:pri-miR-221/222 ratio was
strongly reduced in primary AML cells compared to PB
and BM cells from healthy donors (Figure 2B). This could
indicate that a pri-miR-221/222 processing defect is
acquired during leukemogenesis, or that hematopoietic
cells have an a priori limited pri-miR-221/222 processing
capacity that becomes saturated when this pri-miRNA is
transcriptionally upregulated in the context of leukemia.
pri-miR-221/222 is universally overexpressed in AML
The experiments shown in Figure 2B had revealed that
pri-miR-221/222 was overexpressed to a substantially
higher degree than its mature derivatives in AML versus
healthy controls. Analysis of additional primary PB samples
confirmed that pri-miR-221/222 levels were strongly
elevated in AML (mean, 72.4-fold; median, 50.3-fold;
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6 healthy PB samples, Figure 3A). Similar results were
obtained with BM samples (Figure 3B).
pri-miRNAs are not generally overexpressed in AML
Since pri-miRNA processing involves both general and
miRNA specific factors [17,19-21], the limited processing
capacity apparent in AML could be exclusive to pri-
miR-221/222 or affect other pri-miRNAs as well. To
address this question, 6 AML and 3 normal PB samples
were subjected to qRT-PCR for pri-miR-15b, pri-miR-17,
pri-miR-21, and pri-miR-223. These pri-miRNAs were
chosen because the corresponding mature miRNAs were
readily detectable in our microarray analyses, and exhibited
different patterns of expression in AML and healthy
controls (Additional file 3: Table S3). While mature
miR-15b was downregulated in AML (Additional file 3:
Table S3), the corresponding pri-miRNA was consistently
and significantly overexpressed, albeit to a lesser extent than
pri-miR-221/222 (Figure 4A,C). Pri-miR-17, pri-miR-21
and pri-miR-223 were elevated even more moderately and
in a non-significant manner (Figure 4B,D,E). These results
suggest that AML cells have a limited processing capacity
affecting some, but not all, pri-miRNAs, with a particu-
larly strong effect on pri-miR-221/222.
The pri-miR-221/222 transcript overexpressed in AML
is at least 23 kb long
The pri-miR-221/222 transcript was previously reported
to be ~2.1 kb in size in breast cancer cells [50]. However,
publically available global run-on sequencing (GRO-Seq)
data from IMR90 primary lung fibroblasts, showing the
density of RNA polymerase involved in transcription
[42], and RNA-seq data from Hs27 foreskin fibroblasts
(IV, manuscript in preparation) indicated the possible exist-
ence of pri-miR-221/222 transcripts of 28.2 and 108.5 kb,0
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To investigate whether any of these transcripts was
expressed in AML, we designed primer pairs for regions
near the 5’-ends of each of them, and another pair for a
region 3’ of miR-221 (Figure 5A). qRT-PCR on 3 AML
and 2 healthy control PB samples showed that the
amplicons near the predicted 5’-ends of the 5.6 and
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behaviour (Figure 5B-F). Even though these experiments
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to +45 and from +17 to +1952 relative to the estimated
start site of the predicted 28.2 kb transcript were cloned
into the luciferase reporter vector pGL3-Promoter to yield
plasmids pGL3-P(−1874/+45) and pGL3-P(+17/+1952).
Because human hematopoietic cell lines are notoriously
difficult to transfect, luciferase assays were performed in
readily transfectable adherent cell lines. The luciferase
activity of pGL3-P(+17/+1952) was approximately 13-fold
higher than that of empty pGL3-P in MCF7 cells, while the
upstream fragment increased the transcriptional activ-
ity of the reporter only about twofold (Figure 5G).
Comparable results were obtained in 293 T and HeLa
cells (Additional file 6: Figure S2). These data confirmthat a region in the immediate vicinity of the predicted
pri-miR-221/222 TSS can indeed promote transcription in
human cells.
pri-miR-221/222 levels reflect the disease stage in AML
Finally, we asked whether pri-miR-221/222 expression
would reflect the disease stage in AML. qRT-PCR on
paired samples from four AML patients from the time
of diagnosis and remission showed that pri-miR-221/222
expression was high at the former time point, and declined
to control levels at the latter (Figure 6A). In contrast, when
paired diagnostic and relapse samples from three AML
patients were examined, pri-miR-221/222 expression was
comparable between the two time points (Figure 6B).
050
100
150
200
250
300
R
LU
pGL3P construct
G
empty (-1874/+45) (+17/+1952)
BA
pr
i-m
iR
-2
21
/2
22
 le
ve
ls
#
0
50
100
150
200
250
C
pr
i-m
iR
-2
21
/2
22
 le
ve
ls
5.
6 
kb
a
m
pl
ico
n
#
AML NPB
D
pr
i-m
iR
-2
21
/2
22
 le
ve
ls
28
.2
 k
b
a
m
pl
ico
n
#
AML NPB
E
pr
i-m
iR
-2
21
/2
22
 le
ve
ls
10
8.
5 
kb
a
m
pl
ico
n
#
AML NPB
F
pr
i-m
iR
-2
21
/2
22
 le
ve
ls
3‘
a
m
pl
ico
n
#
AML NPB
0
20
40
60
80
100
120
AML NPB
0
500
1000
1500
2000
2500
0
20
40
60
80
0
20
40
60
80
3000
Figure 5 The pri-miR-221/222 transcript overexpressed in AML is at least 23 kb long. A) Deep sequencing data and chromatin marks in
the relevant region in chromosome band Xp11.3 indicate that 5.6 kb, 28.2 kb, and/or 108.5 kb pri-miR-221/222 transcripts may exist. UCSC genome
browser screenshot of chrX: 45,420,000-45,650,000, hg18, showing RNA-seq data from Hs27 foreskin fibroblasts (Vlatkovic IM, unpublished results),
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and H3K36me3 (brown) in GM12878, K562, H1-hESC, HepG2, HUVEC, and HMEC cells [51], the positions of mature miR-221 and miR-222, the positions
of primers used for qRT-PCR, and the putative pri-miR-221/222 transcripts (arrows). B-F) qRT-PCR on 3 blast-enriched AML and 2 healthy control PB
samples using primers surrounding mature miR-221 (B), primers near the predicted 5’-ends of the 5.6 kb (C), 28.2 kb (D), and 108.5 kb (E) transcripts,
and near the 3’ end common to all predicted transcripts (F). Transcript levels were determined by qRT-PCR and normalized to those of the
housekeeping gene ß-2-microglobulin using the ΔΔct method [40] and PB from donor A (marked with #) as a calibrator. Note the differences in scale
of the y-axis between the different panels. G) Luciferase assays demonstrate transcription activating potential of a region near the predicted start site
of the 28.2 kb transcript. pGL3-P(−1874/+45), pGL3-P(+17/+1952), and the parental vector pGL3-P were transiently transfected into MCF7 cells, and
luciferase activities were determined 2 days later. To control for transfection efficiency, firefly luciferase activity was normalized to renilla luciferase
activity expressed from a cotransfected plasmid. Data represent mean +/− SEM from three biological replicates.
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5’-end of the putative 28.2 kb transcript (data not shown).
Discussion
To identify miRNAs potentially contributing to leukemo-
genesis, the miRNA expression profiles of 52 AML samples
were compared to those of hematopoietic cells from 13
healthy donors. Using microarrays containing highly
specific LNA probes for over 600 human miRNAs - a
substantially larger number than in most previous
studies - 64 miRNAs were found to be misexpressed in
AML in a statistically significant manner. Interestingly,
subsequent studies on miR-221, one of the miRNAs
most consistently overexpressed in AML, revealed a
limited capacity of malignant myeloid cells to process
its precursor forms. Firstly, only precursor, but not mature
miR-221 levels were increased after introduction of appro-
priate expression vectors into several different humanhematopoietic cell lines, and secondly, primary AML cells
overexpressed pri-miR-221/222 to a much higher extent
than its mature products. Because processing of vector-
borne miRNA precursors, like that of endogenous pri-
miRNAs, requires consecutive cleavage by Drosha and
Dicer, the most plausible explanation of these results is a
limited pri-miR-221/222 processing capacity at the Drosha
level. pri-miR-221/222 overexpression was present in a
high proportion of the patients investigated in this study
(84%; 31/37 patients in the experiment shown in Figure 3,
using the mean plus 3 standard deviations of the re-
spective healthy controls as a cutoff for overexpression),
so that the conclusion appears justified that it is a common
phenomenon in AML. Underscoring the association
between pri-miR-221/222 overexpression and AML,
analysis of samples from the times of diagnosis, remission,
and relapse showed that pri-miR-221/222 levels faithfully
reflected the stage of disease.
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present in AML, pathologically increased transcription on
the background of a physiologically limited processing
capacity, or an acquired processing deficiency on the
background of unaltered transcriptional activity may
be considered. In disfavour of the latter possibility, a
processing defect at the Drosha level does not necessarily
lead to an accumulation of pri-miR molecules [52-56].
Also, it could not easily be reconciled with our own and
published [12,24,25,44] observations that mature miR-221
and 222 are not down-, but upregulated in AML. Increased
transcription of pri-miR-221/222, in concert with a limited
capacity of hematopoietic cells to process this molecule,
therefore likely accounts for its induction in AML. Thishas not been proven, however, and will be the subject of
future investigations.
A role for restricted miRNA processing capacities in
tumor cells as well as in developmentally immature cells
has been previously suggested by Thomson et al. [53].
These authors found that mature let-7 g was almost
undetectable in embryonic stem (ES) cells and P19
teratocarinoma cells, although the corresponding pri-
miRNA was as abundant as in E14.5 embryos and dif-
ferentiated P19 cells, which expressed high levels of let-7 g.
Similarly, decreased expression of 22 miRNAs in a panel of
human tumors of various origins was not accompanied by
a reduction in the corresponding pri-miRNAs, indicating
that it was due to an acquired processing defect rather than
Rommer et al. BMC Cancer 2013, 13:364 Page 10 of 12
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show that in AML transcriptional upregulation on the
background of a probably a priori limited processing cap-
acity causes an elevation of pri-miR-221/222 levels. Despite
of these differences, both studies concur to suggest a role
for restricted miRNA processing in tumorigenesis.
Since pri-miR-221/222 is upregulated in a large majority
of AML, either this overexpression per se or an event
leading to it should be essential for leukemogenesis. In
principle, elevation of pri-miR-221/222 levels could be
a bystander effect of the induction of a nearby oncogene.
However, according to human genome assembly 19
(http://genome.ucsc.edu/) no known genes are located
within a genomic region that extends from 0.7 Mb
centromeric to 0.5 Mb telomeric of the mature miR-221
sequence. Also, co-activation of pri-miR-221/222 with an
adjacent oncogene would not be able to explain why other
pri-miRNAs are also overexpressed in AML. Alternatively,
a transcription factor whose deregulation contributes to
misexpression of cancer genes could also activate pri-
miR-221/222 and other pri-miRNAs in trans. The possible
identity of such a transcription factor is presently obscure.
Thirdly, an acquired pri-miRNA processing deficiency
might contribute to leukemogenesis by diminishing the
production of mature miRNAs. This appears unlikely for
the reasons outlined above. Fourth, inhibition of pri-
miRNA processing could be a side effect of mutations
whose primary oncogenic effect is unrelated to miRNA
biogenesis. For example, mutations inactivating the tran-
scriptional competence of p53 also interfered with miRNA
processing [57]. However, this defect was not accompan-
ied by increased pri-miRNA levels [57], and furthermore
p53 mutations are infrequent in AML [58], so that such a
mechanism remains speculative at present.
Thus, even though a number of possibilities can be
conceived to explain pri-miR-221/222 overexpression as
a bystander effect of other oncogenic events, at present
none of these is sufficiently plausible to discredit the
possibility that pri-miR-221/222 may itself act as an
oncogene. lncRNAs have recently received great attention
as possible cancer genes with diverse ways of action, e.g.
the regulation of chromatin and transcription [59], and pri-
miRNAs may represent a novel type of lncRNA. In a recent
study, the primary transcripts of the let-7 family of miRNAs
(pri-let-7) were reported to be able to regulate gene expres-
sion [22], thus ascribing a biochemical function to this
type of molecule. Furthermore, some lncRNAs have been
reported to serve as precursors for small RNA species in
addition to their well described functions as macro ncRNAs
[23,60]. Of particular interest, H19, an imprinted RNA that
is overexpressed in many tumors and displays oncogenic
functions [61,62], has been found to host a miRNA [63]. It
can therefore be considered as an example of a pri-miRNA
that at the same time acts as an oncogenic lncRNA.Conclusion
In this study we identified 64 miRNAs that were differen-
tially expressed between AML and healthy controls, and
may therefore contribute to leukemogenesis. Moreover, we
found that pri-miR-221/222 was strongly overexpressed,
but inefficiently processed, in a large proportion of AML,
indicating that it may represent a novel molecular marker
and a putative oncogene in this disease.Additional files
Additional file 1: Table S1. Patient and control samples used in this
study. A) Healthy controls; B) AML samples used for miRNA microarray
analyses and qRT-PCR; C) additional AML samples used for qRT-PCR; D) AML
patients with follow-up samples. Cytogenetic risk categories for AML were
defined as follows: t(8;21), inv(16), t(15;17), favorable; normal karyotype, other
abnormalities, intermediate; 3q21q26 abnormalities, 5q-/-5, 7q-/-7, 11q23
abnormalities, 12p abnormalities, 17p abnormalities, complex aberrant
karyotypes (greater than or equal to 3 abnormalities, excluding cases with t
(8;21), inv(16), and t(15;17)), unfavorable.
Additional file 2: Table S2. A) Primers used for Sybr Green based qRT-
PCR. Fwd, forward, rev, reverse. Unless specifically mentioned otherwise,
pri-miR-221/222 was measured with the primers pri-miR-221/222 fwd and
rev, which partially overlap with the miR-221 precursor sequence. B)
Primers used to amplify and clone the promoter of the putative 28.2 kb
pri-miR-221/222 transcript. Fwd, forward, rev, reverse. The transcription
initiation site as predicted based on deep sequencing and histone mark
data was defined as position +1. The SacI and XhoI restriction sites added
for the purpose of cloning are underlined.
Additional file 3: Table S3. miRNAs significantly differentially expressed
between AML and control samples according to microarray analyses.
Separate comparisons were performed between AML and the three types
of controls (CD34+; normal BM, NBM; and normal PB, NPB). Only miRNAs
that were expressed in at least half of the relevant samples were considered
for each comparison. Correction for multiple hypothesis testing was
performed according to Benjamini and Hochberg [43]. False discovery rates
(FDRs) <0.05 are highlighted in grey. log2 ratios between mean expression
values in AML and controls are also indicated; positive values indicate that a
miRNA is expressed at higher levels in AML than in the respective control.
Additional file 4: Table S4. miRNAs associated with preclinical or clinical
parameters in AML. Associations between miRNA levels and sex, age, FAB
type, white blood cell count, blast percentage, lactate dehydrogenase (LDH)
levels, cytogenetic risk, and achievement of complete remission (CR) were
determined as described in Methods. rho, Spearman’s rank correlation
coefficient; pbsr, point biserial correlation coefficient; FDR, false discovery
rate according to Benjamini and Hochberg [43].
Additional file 5: Figure S1. Human hematopoietic cell lines, but not
HeLa cells, fail to process vector borne miR-221. A) Human myeloid cell lines
HL60, KG1, and KG1a were infected with pEZX-MR03-miR-221 or scrambled
control vector and sorted for GFP positivity. Levels of mature miR-221 were
determined by Taqman qRT-PCR and normalized to those of RNU6B using
the ΔΔct method [40]. For each cell line, non-infected cells were used as a
calibrator (not shown). B) HeLa cells were transiently transfected with pEZX-
MR03-miR-221 or scrambled control vector. 2 days later, miR-221 expression
was measured as in A. C) GFP positive, pEZX-MR03-miR-221 or control
infected HL60, KG1, and KG1a cells were subjected to qRT-PCR for the vector
borne precursor form of miR-221. Expression levels were normalized to those
of ß-2-microglobulin, using non-infected cells as a calibrator (not shown).
Additional file 6: Figure S2. Promoter activity of a region near the
predicted start site of the 28.2 kb pri-miR-221/222 transcript. The parental
vector pGL3-P and its derivatives pGL3-P(−1874/+45) and pGL3-P(+17/
+1952) were transiently transfected into 293 T (A) or HeLa (B) cells, and
luciferase activities were determined 2 days later. To control for
transfection efficiency, firefly luciferase activity was normalized to renilla
luciferase activity expressed from a cotransfected plasmid.
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